Ramen spectroscopy

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has opened a new center at its facility in Tewksbury, Mass., it announced today.

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

ICAP Ocean Tomo has conducted due diligence to rate the strength of the patents and is marketing the portfolio to various healthcare and other companies that might be interested in commercializing the technology, which can be used to monitor a patient's blood glucose or substances in the brain and cerebrospinal fluid.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.